Page 10 - The Flying Publisher Guide to Hepatitis C Treatment

10 |

Therapeutical strategies................................................... 45
Practical approach to retreatment.................................. 49
How to manage genotype 2 and 3 non-responders and
relapsers ? .............................................................................. 50
Nonresponders/relapsers infected with HCV G2/3 ....... 50
Retreatment of HCV genotype 2 and 3 patients............. 51
Special categories of patients............................................... 52
Injecting drug users (IDUs) .............................................. 52
Hemodialysis patients ...................................................... 53
Patients with psychiatric comorbidities......................... 54
Patients with inherited anemias...................................... 54
African Americans ............................................................ 55
HIV-HCV coinfection ........................................................ 55
Outlook ................................................................................... 57
Links........................................................................................ 57
4. Searching for new antiviral therapies..................................... 58
Candidates for new therapeutic approaches....................... 58
New IFN formulations ........................................................... 59
Alternative RBV formulation................................................ 64
Direct-Acting Antivirals (DAAs) ........................................... 65
Protease inhibitors (PIs)................................................... 65
Triple therapy ................................................................... 66
Other investigational HCV PIs ......................................... 69
HCV polymerase inhibitors.............................................. 70
NS5A inhibitors ................................................................. 72
Host cyclophilins inhibitors............................................. 73
Emergence of drug resistant mutations.......................... 73
What does the future hold? .................................................. 74
Outlook ................................................................................... 76
Links........................................................................................ 77